This article was originally published in The Gray Sheet
Theratronics acquisition will become an operating division of the parent company's MDS Nordion business under the recent acquisition agreement ("The Gray Sheet" June 1, p. 4). MDS maintains that there is no product overlap between the firms in the distribution of cobalt-60 since MDS Nordion supplies low specific activity cobalt-60 to the industrial irradiation market for gamma sterilization and Theratronics supplies high specific activity cobalt-60 sources for radiotherapy equipment. In addition, MDS Nordion's 1995 licensing agreement was with Theragenics, not Theratronics
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.